Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell Ml\IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIXQOphKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKDNwNk\lMVA2KM7:TR?= M1\zS3NCVkeHUh?=
CAL-51 cell NWDxXGFDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYXMeHVOUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF{NjDuUS=> NWfDZng2W0GQR1XS
ABC-1 cell MlXGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jB[mlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?= M1XOVXNCVkeHUh?=
A2780 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fKeGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6PCCwTR?= NHrWVmhUSU6JRWK=
ES1 cell M3XzdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3f0U2lvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? MX7TRW5ITVJ?
HUTU-80 cell M3K2Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnu[llSUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OUGgcm0> NGXBeJBUSU6JRWK=
NCI-H292 cell M1vidmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkP0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDh4IH7N NE\rfIFUSU6JRWK=
NB69 cell M2rXPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjiPWpLUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?= MV3TRW5ITVJ?
ES8 cell NG\PUY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{Kgcm0> NWi2cnRxW0GQR1XS
BCPAP cell NVXHfmhiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnJTY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Qhdk1? NUm4N5N4W0GQR1XS
T-24 cell NIXGXmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPmbllKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2KG6P NH3IdpFUSU6JRWK=
EW-16 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYHvN2pYUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjFibl2= M2PCWHNCVkeHUh?=
OVCAR-5 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnr3TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?= MWfTRW5ITVJ?
SF126 cell NXLXWodXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnLsTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVUhdk1? NHfXc4xUSU6JRWK=
KP-4 cell M{LqWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\MTY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6xO{BvVQ>? NHv1V3lUSU6JRWK=
GAMG cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUnE[Y5JUW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42OSCwTR?= Ml3GV2FPT0WU
HOS cell NUTlRZh[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfyZVhKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVMhdk1? MofFV2FPT0WU
CHL-1 cell M1jHcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjQcIM2UW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDFibl2= M2\6TXNCVkeHUh?=
AGS cell MmrTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWfYfVVUUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P NGfIT|FUSU6JRWK=
MDA-MB-157 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHv5c|FKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyJI5O Ml\VV2FPT0WU
HSC-3 cell MnntS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wNkBvVQ>? M{HzT3NCVkeHUh?=
CAL-72 cell Mon4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC15MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? MnjzV2FPT0WU
NBsusSR cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1H3e2lvcGmkaYTpc44hd2ZiaIXtZY4hVkK|dYPTVkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTNibl2= NFf3TXVUSU6JRWK=
ES7 cell NXT5dGNMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLic29LUW6qaXLpeIlwdiCxZjDoeY1idiCHU{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlU6KG6P M1XIZ3NCVkeHUh?=
H-EMC-SS cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2LGZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N Mn25V2FPT0WU
NCI-H1703 cell NHjFV|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXjzW4lXUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4ODNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4JI5O NVzjZZFiW0GQR1XS
BHT-101 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlczKG6P NFW3WVZUSU6JRWK=
SK-OV-3 cell NYXISIJ[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVryO3F7UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> MmLUV2FPT0WU
EW-24 cell NGLLRpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGmwUZFKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OyCwTR?= M{LoTXNCVkeHUh?=
PSN1 cell MkPWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXHlVWlCUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45PCCwTR?= MUDTRW5ITVJ?
OVCAR-8 cell M4j1WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1;pOmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= NIG2XlBUSU6JRWK=
NCI-H1563 cell MlTVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnTVTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF|IH7N M4PKWHNCVkeHUh?=
SW756 cell M4XTXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEX5d41KdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOyCwTR?= NG\aVVlUSU6JRWK=
A375 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX;oe2lVUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yPCCwTR?= M37LU3NCVkeHUh?=
Ca9-22 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3f3XWlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zPSCwTR?= MmTWV2FPT0WU
SW1990 cell NYC0TFF2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXewclRzUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G5PVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjN{IH7N NWDBPZY1W0GQR1XS
ES4 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwM{mgcm0> MmXEV2FPT0WU
HCE-T cell M1XxdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHnHN5dKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PSCwTR?= M1;UVHNCVkeHUh?=
MOLT-16 cell NV7DVpZHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFXuPJNKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV|IH7N MUnTRW5ITVJ?
HSC-4 cell MnzmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND64JI5O M4XTTnNCVkeHUh?=
NCI-SNU-1 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4PQXmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=> MVvTRW5ITVJ?
EW-11 cell Mo\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MojyTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPUBvVQ>? MkPqV2FPT0WU
HT-1080 cell Mn24S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHhTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46QSCwTR?= Mk\QV2FPT0WU
MES-SA/Dx5 cells NI[5TpBEgXSxdH;4bYNqfHliYYPzZZk> NHTJ[WREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0> NGX5[ZozOzl|N{m4NS=>
SW1710 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPOTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlE3KG6P MmfLV2FPT0WU
EW-1 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYLIWmUzUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zPCCwTR?= NWHWN|NUW0GQR1XS
BV-173 cell Mmm0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFfkOWlKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2= NFv0OFBUSU6JRWK=
TE-8 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVrJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkSxJI5O MmWwV2FPT0WU
G-401 cell NUnZOpk3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIGxOJFKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41OyCwTR?= M{jtenNCVkeHUh?=
KOSC-2 cell NVvIeWZpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3zuO2lvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?= M2LUcXNCVkeHUh?=
HuCCT1 cell NUXzUW9qT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV3aTI1[UW6qaXLpeIlwdiCxZjDoeY1idiCKdVPDWFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV{IH7N M{\KW3NCVkeHUh?=
FADU cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGZCTFViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2JI5O NVrwPFlNW0GQR1XS
MHH-ES-1 cell NFPXTI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvEV|g2UW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkmgcm0> M3TtSHNCVkeHUh?=
ES3 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmP0TY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5JI5O NFjGPHNUSU6JRWK=
OVCAR-4 cell NH\DZlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7vTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU45PyCwTR?= MV3TRW5ITVJ?
HD-MY-Z cell M3XnRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIHaeGJKdmirYnn0bY9vKG:oIHj1cYFvKEiGLV3ZMXoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjlzIH7N M1TYc3NCVkeHUh?=
human JAR cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUegcm0> NUHRVIQzW0GQR1XS
A427 cell M{XzWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MojMTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6wO{BvVQ>? MkjiV2FPT0WU
697 cell NFjqWGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF64SYpKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVMhdk1? NHnBPGxUSU6JRWK=
OVCAR-3 cell NGjx[XFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2rHd2lvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOiCwTR?= MWnTRW5ITVJ?
human NB14 cell M4DFSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWLOU|FGUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PCCwTR?= MnrtV2FPT0WU
GB-1 cell NFfzXZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4XodWlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uO|Ehdk1? NXHafoJmW0GQR1XS
COR-L105 cell M1jJSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEfX[JZKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi55NjDuUS=> NI[1XIpUSU6JRWK=
647-V cell M1HiZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIPse|NKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P NV[5V5hGW0GQR1XS
human K5 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF[2UIlKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NzDuUS=> NVTFdFBYW0GQR1XS
DMS-273 cell NVK1PY4zT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHT4Z5BKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N M3nkeXNCVkeHUh?=
UM-UC-3 cell NYfERpFtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkjwTY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= M3fKe3NCVkeHUh?=
HEL cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTITY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkC4JI5O MUHTRW5ITVJ?
human KU-19-19 cell M1LLd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlrMTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODlibl2= M37ieHNCVkeHUh?=
MC-IXC cell M3TFT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUjJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNVchdk1? NUD2OVlIW0GQR1XS
human H4 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5{NTDuUS=> NVf4O5lIW0GQR1XS
NUGC-3 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnPXTY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P M3m1ZXNCVkeHUh?=
CHP-212 cell MnjTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM1KG6P NXTDfnRxW0GQR1XS
human SW982 cell NWeyXWNIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mo\mTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOFQhdk1? MlTzV2FPT0WU
C-33-A cell M3nxZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnHyTY5pcWKrdHnvckBw\iCqdX3hckBENTN|LVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlU5KG6P MnrJV2FPT0WU
PC-3 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHWTY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PUBvVQ>? MUfTRW5ITVJ?
COLO-684 cell NWnRTJRIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4zOSCwTR?= NWTwe3dXW0GQR1XS
SNU-387 cell MkHuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHNPXS1|OEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlQ6KG6P NYn5fZk6W0GQR1XS
U251 cell NWPwXJh{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2JI5O MXPTRW5ITVJ?
A673 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGE3PzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT62JI5O NUXBOpozW0GQR1XS
human T47D cell MkLGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>? M{TTUHNCVkeHUh?=
A549 cell M{i2dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O NVS1V2JFW0GQR1XS
PC-14 cell MmfQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NILZbm1KdmirYnn0bY9vKG:oIHj1cYFvKFCFLUG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzNibl2= MXvTRW5ITVJ?
A704 cell NVrBdZBGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>? MojIV2FPT0WU
MCF7 cell MoTaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFryUppKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?= NEiwe3BUSU6JRWK=
PC3 cells MnX0SpVv[3Srb36gZZN{[Xl? NHHUeVhKdmirYnn0bY9vKG:oIGDET|EudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhicnXzbYR2\SCrbjDoeY1idiCSQ{OgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC5zMUOg{txO MXqyNVM1OTZ5NR?=
F-36P cells MYXQdo9tcW[ncnH0bY9vKGG|c3H5 M33ycmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1? MoT0NlE{PDF4N{W=
OCI-AML2 cells NIjSd4ZRem:uaX\ldoF1cW:wIHHzd4F6 MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN|Uh|ryP MViyNVM1OTZ5NR?=
K562 cells NUf0c|dXWHKxbHnm[ZJifGmxbjDhd5NigQ>? NEezOZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOsJGlEPTB;MUig{txO M2PCZlIyOzRzNke1

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Unknown status Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID